ATOSSA THERAPEUTICS, INC. — Form 8-K
Filed October 9, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Atossa Therapeutics executed a Stapled Contingent Value Rights Agreement on October 8, 2026, declaring one CVR per share of common stock outstanding as of October 19, 2026 record date. CVR holders are entitled to 25% of net proceeds from monetization of Atossa's first qualifying FDA priority review voucher, capped at $50 million aggregate. The CVRs remain attached to common stock unless detached by the Board; no payments are triggered unless/until a qualifying voucher is awarded and monetized.
Why this rating
CVRs are contingent and speculative; no voucher yet awarded. $50M cap is 47% of company's $107M market cap but represents zero cash today—standard equity incentive structure for biotech shareholders. Administrative event.
See more from October 9, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.